Shilpa Medicare launched the anti-cancer drug Dasashil

Shilpa Medicare launched its generic version of cancer drug Dasatinib. The monthly therapy cost of Rs.6,440. The company launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name “Dasashil.”

Dasashil:
♦ Dasashil, the branded generic anti-cancer drug, will be available in all dosage strengths of 20 mg, 50 mg, 70 mg, and 100 mg tablets. 
♦ The drug is used for the treatment of Chronic Myeloid Leukaemia (CML). 
♦ Dasashil will revolutionize the treatment by ensuring to make therapy available for more Indian patients due to increased affordability. 
♦ The products are being manufactured and supplied from the company’s US Food and Drug Administration (FDA) approved manufacturing facility.
♦ The drug can benefit around 10,000 to 15,000 new patients of CML in India.